Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial

Documenti analoghi

• Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial
  di: Pierre Fayoux, et al.
  Pubblicazione: (2025)
• Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial
  di: Pierre Fayoux, et al.
  Pubblicazione: (2024)
• Functional outcomes in children and adolescents with neurodisability accessing music therapy: A scoping review
  di: Karen Twyford, et al.
  Pubblicazione: (2024)
• Hospital admissions and school absences of primary school children with and without neurodisability
  di: Laura Gimeno, et al.
  Pubblicazione: (2025)
• Hospital admissions and school absences of primary school children with and without neurodisability
  Pubblicazione: (2026)